2 completed, 1 terminated, 1 unknown. 4 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 4 | Completed 2, Terminated 1, Unknown 1 |
Follow E7046: new trials by email Literature Review of E7046 trials Research Report on E7046
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Double/Triple Combinations of AN2025, AN0025 and Atezolizumab in Advanced Solid Tumors AN2025, AN0025, Atezolizumab 1200 mg in 20 ML Injection - Locally Advanced Solid Tumor | Phase 1 | Completed | Adlai Nortye Biopharma Co., Ltd. | 47 | 2021-09-07 | 2025-06-22 |
| AN0025 and Pembrolizumab Combination in Advanced Solid Tumors AN0025, Pembrolizumab - Triple-negative Breast Cancer, NSCLC, Squamous or Non-Squamous | Phase 1 | Unknown | Adlai Nortye Biopharma Co., Ltd. | 63 | 2020-08-20 | 2024-06-27 |
| Preoperative Radiotherapy and E7046 in Rectum Cancer E7046, Long Course Chemoradiotherapy (LCRT), Short Course Radiotherapy (SCRT) - Neoadjuvant Therapy in Rectal Cancer | Phase 1 | Completed | Adlai Nortye Biopharma Co., Ltd. | 29 | 2017-05-17 | 2021-10-04 |
| Study of E7046 in Subjects With Selected Advanced Malignancies E7046 - Tumors | Phase 1 | Terminated | Eisai Inc. | 31 | 2015-07-30 | 2020-02-17 |
Carcinoma, Non-Small-Cell Lung (1) · Colorectal Neoplasms (1) · Neoplasms (1) · Rectal Neoplasms (1) · Spinocerebellar Degenerations (1) · Triple Negative Breast Neoplasms (1) · Uterine Cervical Neoplasms (1)
Adlai Nortye Biopharma Co., Ltd. (3) · Eisai Inc. (1)
United States (4) · France (2) · Poland (1) · United Kingdom (1)
Robert Atkinson, Ph.D. (1) · Robert Atkinson, PhD, MSCR (1)
2014 (1), 2016 (1), 2019 (1)